Participated · Equity · Jun 2026

KLIPY offers an expression API layer that enables developers to integrate GIFs, memes, stickers, clips, and AI media into social and creative platforms. Its platform provides developer infrastructure, creator tools, content rights and distribution controls, and monetization solutions including contextual ad tools. The company cites integrations with apps and platforms such as BeReal, Baidu, Canva, Figma, and Microsoft SwiftKey, and reports nearly 10,000 developers and 40,000 creators using its API, which processes billions of requests weekly. KLIPY plans to use the recent funding to expand product, engineering, and go-to-market teams, broaden platform integrations, and build new monetization and creative tools for creators and content studios. It was founded by serial entrepreneurs Givi Beridze, Frank Nawabi, and Waska Chaduneli; Nawabi previously founded GIF-sharing platform Tenor. KLIPY positions itself as a privacy-conscious expression layer for the AI era focused on enabling expressive media at scale.

Participated · Series D · Jan 2026

Cellares builds and operates fully automated platforms for cell therapy manufacturing, including the Cell Shuttle for end-to-end manufacturing and Cell Q for automated in-process and release quality control. The company says its automation delivers industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10× more cell therapy batches than conventional CDMOs with comparable footprint and headcount. The Cell Shuttle has received the FDA's Advanced Manufacturing Technology (AMT) designation and the company reports a 100% automation success rate across more than a dozen automated processes. Cellares has achieved clinical validation milestones such as a successful IND amendment enabling active clinical manufacturing on the Cell Shuttle and the dosing of first patients in a partner clinical trial across multiple therapeutic areas and modalities. Headquartered in South San Francisco, Cellares operates a commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, and has additional facilities under construction in Europe and Japan. The company is positioning its network of IDMO Smart Factories to support both clinical and commercial programs and to expand access to cell therapies worldwide.

Participated · Series B · Nov 2025

VahatiCor, Inc. is focused on transforming cardiac care for the millions of patients suffering from Coronary Microvascular Dysfunction, a condition that causes angina despite the absence of large-artery blockages. Its core product, the A-FLUX® Reducer System, is a repositionable, self-expanding device that creates a controlled narrowing of the coronary sinus to redistribute oxygenated blood and improve myocardial perfusion. The company is currently running the SERRA-I early feasibility study, which will enroll 30 patients across six clinical sites to evaluate safety and efficacy. Proceeds from the latest financing will also fund continued engineering work and preparations for pivotal trials and regulatory interactions. Investors highlight the device’s potential to become the leading coronary sinus therapy due to its procedural safety and efficacy advantages. Following its $23 million Series B, VahatiCor has the capital needed to progress through key clinical milestones and move closer to market introduction of its breakthrough therapy.

Participated · Series B · Nov 2025

Santa Barbara-based Sovato provides software and connectivity that lets health systems safely scale telesurgery programs by linking expert surgeons to distant robotic surgical systems. The platform is device-agnostic, already integrated with several leading robots, and has proven safety and feasibility in pre-clinical cases conducted hundreds to thousands of miles apart both domestically and internationally. By allowing a hub-and-spoke model in which one surgical team can serve multiple sites, Sovato helps address global surgeon shortages and geographic disparities in care. The company is collaborating with healthcare providers, robotic manufacturers, and standards bodies to establish operational guidelines for remote robotic surgery programs. Market tailwinds are strong, with the global robotic surgery sector projected to grow 12.4% annually through 2030 and more than 246 companies active in the space. Founded by Cynthia Perazzo and surgical robotics pioneer Dr. Yulun Wang, Sovato has raised $41 million to date, including its recent Series B, to accelerate product development and deepen industry partnerships.

Participated · Series C · Sep 2025

Galvanize Therapeutics develops and commercializes a pulsed electric field (PEF) platform that uses non-thermal, short-duration, highly focused electrical pulses to modulate biologic processes. Its lead programs include the Aliya® PEF system for solid tumors and RheOx® therapy for chronic bronchitis. The company is commercial-stage and intends to expand its commercial footprint in the United States. Galvanize plans to advance clinical and development activities across its oncology and chronic lung disease programs. Management says it will continue to innovate its novel, non-pharmacologic PEF platform to address unmet needs in patients underserved by pharmaceutical approaches. The company is based in Redwood City, California. Galvanize Therapeutics commercializes the Aliya Pulsed Electric Field (PEF) energy platform, a non-thermal high-voltage, high-frequency electrical system designed to alter cellular physiology for ablation and drug delivery. The company has multiple product lines: RheOx for chronic bronchitis (CE Mark, launched in select European hospitals), CENTAURI for cardiac arrhythmias (CE Mark, launching in Europe), and the Aliya system for soft tissue ablation (recent U.S. FDA 510(k) clearance, launching at select U.S. hospitals). Galvanize is also studying Aliya in immuno-oncology (preclinical and early clinical signals of immune activation) and developing a local drug-delivery system. The company was formed by ATP in 2022 through the merger of Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics and is headquartered in San Carlos, Calif. Management says it is investing to prove safety and demonstrate enhanced outcomes in initial clinical targets while exploring additional platform applications.